CN102775405A - 一种高溶解度的多索茶碱化合物 - Google Patents
一种高溶解度的多索茶碱化合物 Download PDFInfo
- Publication number
- CN102775405A CN102775405A CN2012103034049A CN201210303404A CN102775405A CN 102775405 A CN102775405 A CN 102775405A CN 2012103034049 A CN2012103034049 A CN 2012103034049A CN 201210303404 A CN201210303404 A CN 201210303404A CN 102775405 A CN102775405 A CN 102775405A
- Authority
- CN
- China
- Prior art keywords
- doxofylline
- doxofylline compound
- compound
- compound according
- stirred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004483 doxofylline Drugs 0.000 title claims abstract description 66
- -1 doxofylline compound Chemical class 0.000 title claims abstract description 39
- HWXIGFIVGWUZAO-UHFFFAOYSA-N doxofylline Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1OCCO1 HWXIGFIVGWUZAO-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000126 substance Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- 239000012535 impurity Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 4
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims 1
- 238000002050 diffraction method Methods 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 16
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 description 19
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 239000000843 powder Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229960000278 theophylline Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 208000009079 Bronchial Spasm Diseases 0.000 description 5
- 208000014181 Bronchial disease Diseases 0.000 description 5
- 206010006482 Bronchospasm Diseases 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
- 206010006451 bronchitis Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229960003556 aminophylline Drugs 0.000 description 3
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960004674 theophylline anhydrous Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
测定条件时间 | 含量(%) | 总杂质(%) | 外观 |
光照0天 | 99.93 | 0.04 | 白色粉末 |
光照5天 | 99.94 | 0.05 | 白色粉末 |
光照10天 | 99.93 | 0.05 | 白色粉末 |
高温0天 | 99.93 | 0.04 | 白色粉末 |
高温5天 | 99.92 | 0.04 | 白色粉末 |
高温10天 | 99.93 | 0.05 | 白色粉末 |
高湿0天 | 99.93 | 0.04 | 白色粉末 |
高湿5天 | 99.92 | 0.05 | 白色粉末 |
高湿10天 | 99.91 | 0.05 | 白色粉末 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210303404.9A CN102775405B (zh) | 2012-08-23 | 2012-08-23 | 一种高溶解度的多索茶碱化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210303404.9A CN102775405B (zh) | 2012-08-23 | 2012-08-23 | 一种高溶解度的多索茶碱化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102775405A true CN102775405A (zh) | 2012-11-14 |
CN102775405B CN102775405B (zh) | 2014-03-12 |
Family
ID=47120536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210303404.9A Active CN102775405B (zh) | 2012-08-23 | 2012-08-23 | 一种高溶解度的多索茶碱化合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102775405B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103524503A (zh) * | 2013-10-29 | 2014-01-22 | 天津梅花医药有限公司 | 多索茶碱半水化合物 |
CN111978324A (zh) * | 2020-08-28 | 2020-11-24 | 开封康诺药业有限公司 | 一种多索茶碱的晶型及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4187308A (en) * | 1978-04-06 | 1980-02-05 | Istituto Biologico Chemioterapico "Abc" S.P.A. | Pharmaceutical composition with anti-bronchospasmodic and anti-tussive activity |
CN1106404A (zh) * | 1994-11-03 | 1995-08-09 | 中国科学院上海有机化学研究所 | 新药多索茶碱的合成方法 |
CN102367254A (zh) * | 2011-08-26 | 2012-03-07 | 贺金凤 | 一种更为稳定的多索茶碱化合物及药物组合物 |
-
2012
- 2012-08-23 CN CN201210303404.9A patent/CN102775405B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4187308A (en) * | 1978-04-06 | 1980-02-05 | Istituto Biologico Chemioterapico "Abc" S.P.A. | Pharmaceutical composition with anti-bronchospasmodic and anti-tussive activity |
CN1106404A (zh) * | 1994-11-03 | 1995-08-09 | 中国科学院上海有机化学研究所 | 新药多索茶碱的合成方法 |
CN102367254A (zh) * | 2011-08-26 | 2012-03-07 | 贺金凤 | 一种更为稳定的多索茶碱化合物及药物组合物 |
Non-Patent Citations (1)
Title |
---|
夏春凤: "二恶茶碱(Doxofylline)", 《药学进展》, vol. 15, no. 1, 31 December 1991 (1991-12-31), pages 54 - 55 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103524503A (zh) * | 2013-10-29 | 2014-01-22 | 天津梅花医药有限公司 | 多索茶碱半水化合物 |
CN111978324A (zh) * | 2020-08-28 | 2020-11-24 | 开封康诺药业有限公司 | 一种多索茶碱的晶型及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102775405B (zh) | 2014-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102367254B (zh) | 一种更为稳定的多索茶碱化合物及药物组合物 | |
CN102267957B (zh) | 非布司他a晶型的制备方法 | |
CN103980226A (zh) | 盐酸阿考替胺水合物晶型及其制备方法 | |
CN102702001B (zh) | 稳定的无定型盐酸氨溴索化合物 | |
CN102775405B (zh) | 一种高溶解度的多索茶碱化合物 | |
CN105085612B (zh) | 采用粒子晶体形态优化技术制备的n-(2)-l-丙氨酰-l-谷氨酰胺化合物及制剂 | |
CN107936008B (zh) | 氘代化合物及其医药用途 | |
CN103524503B (zh) | 多索茶碱半水化合物 | |
CN102617584B (zh) | 一种盐酸伊立替康化合物及其药物组合物 | |
WO2020206603A1 (zh) | 2-(2,4,5-取代苯氨基)嘧啶衍生物及其晶形b | |
CN105037361A (zh) | 一种多索茶碱化合物及其药物组合物 | |
CN114644642B (zh) | 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物 | |
CN104829467A (zh) | 盐酸氨溴索二水化合物 | |
CN102824318B (zh) | 一种供注射用的多索茶碱药物组合物 | |
CN104447683A (zh) | 一种稳定的比拉斯汀化合物 | |
CN103626722B (zh) | 一氧化氮供体型降血糖化合物、其制备方法和用途 | |
CN108570045B (zh) | 氢溴酸山莨菪碱的晶型、其制备方法、药物组合物 | |
CN111662186B (zh) | 一种溴己新和反丁烯二酸形成的盐的晶型及制备方法 | |
CN106822228B (zh) | 一种山豆根多糖有效部位及其制备方法 | |
CN104876942B (zh) | 单硝酸异山梨酯半水化合物 | |
CN110003183A (zh) | 2-(2,4,5-取代苯氨基)嘧啶衍生物及其晶形b | |
CN115403538B (zh) | 一种依帕司他晶型及其制备方法和应用 | |
CN103025705B (zh) | 4-甲基苯甲酸4-[2-二甲基胺基-1-(1-羟基环己基)乙基]苯酯盐酸盐的多晶型物、制备方法及其应用 | |
CN104277046B (zh) | 叶绿素降解产物二氢卟吩e6衍生物的金属络合物及其制备方法和应用 | |
CN113993865B (zh) | 一种SGLTs抑制剂的晶型及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121114 Assignee: Kaifeng Kangnuo Pharmaceutical Co., Ltd. Assignor: Tianjin Plum Medicine Co.,Ltd. Contract record no.: 2014120000043 Denomination of invention: High-solubility doxofylline compound Granted publication date: 20140312 License type: Common License Record date: 20140704 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Kaifeng Kangnuo Pharmaceutical Co., Ltd. Assignor: Tianjin Plum Medicine Co.,Ltd. Contract record no.: 2014120000043 Date of cancellation: 20170410 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170428 Address after: 300462 West Binhai New Area of Tianjin Tianjin Development Zone No. 117 105 st Patentee after: TIANJIN MEIHUA BIOLOGICAL PHARMACEUTICAL CO., LTD. Address before: Rong Yuan Road 300384 Tianjin city Nankai District Huayuan Industrial Park No. 9 Patentee before: Tianjin Plum Medicine Co.,Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121114 Assignee: Kaifeng Kangnuo Pharmaceutical Co., Ltd. Assignor: TIANJIN MEIHUA BIOLOGICAL PHARMACEUTICAL CO., LTD. Contract record no.: 2017120000036 Denomination of invention: High-solubility doxofylline compound Granted publication date: 20140312 License type: Common License Record date: 20170518 |
|
EM01 | Change of recordation of patent licensing contract | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20180831 Contract record no.: 2017120000036 License type after: Exclusive license License type before: General permission |